Live Breaking News & Updates on Society of gynecologic oncology annual meeting

2023 Yields Several Promising Trial Updates in dMMR/pMMR Endometrial Cancer

Eirwen M. Miller, MD, highlights data that have impacted the treatment armamentarium for patients with endometrial cancer and mismatch repair–deficient or mismatch repair–proficient disease throughout the course of 2023.

Pennsylvania , United-states , Texas , Houston , West-penn , Shannonn-westin , Eirwenm-miller , Christopherb-morse , Allegheny-health-network , University-of-texas-md-anderson-cancer-center , European-society-for-medical-oncology

Dr Pothuri on the Promise of the RUBY and NRG-GY018 Trials in Endometrial Cancer

Bhavana Pothuri, MD, discusses the promise of the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

Bhavana-pothuri , York-university , Langone-health , Department-of-obstetrics , School-of-medicine , Society-of-gynecologic-oncology-annual-meeting , New-york-university , Gynecologic-oncology-annual-meeting , Nyu-langone-x27s-perlmutter-cancer-center , Onclive-tv , Gynecologic-oncology , Nct03914612

Dr Pothuri on the Phase 3 NRG-GY018 and RUBY Trials in Endometrial Cancer

Bhavana Pothuri, MD, discusses the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

Bhavana-pothuri , Department-of-obstetrics , School-of-medicine , Society-of-gynecologic-oncology-annual-meeting , York-university , Langone-health , New-york-university , Gynecologic-oncology-annual-meeting , Nyu-langone-x27s-perlmutter-cancer-center , Onclive-tv , Gynecologic-oncology , Phase-3-nrg-gy018-

GSK receives EMA validation for Jemperli plus chemotherapy - DirectorsTalk Interviews

GSK receives EMA validation for Jemperli plus chemotherapy

Hesham-abdullah , Tesaro-inc , European-medicines-agency , Society-of-gynecologic-oncology-annual-meeting , Company-type-ii-variation , European-commission , European-society-for-medical-oncology-virtual-plenary , Global-head-of-oncology-development , Anaptysbio-inc , Committee-for-medicinal-products-human , Medicinal-products , Human-use

GSK : European Medicines Agency validates marketing authorisation application for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer - Form 6-K

European Medicines Agency validates marketing authorisation application for Jemperli plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer

. | April 25, 2023

Middlesex , United-kingdom-general- , United-kingdom , Philadelphia , Pennsylvania , United-states , Brentford , Hounslow , London , City-of , Treasure-island , Washington

Top news from SGO: Updates in endometrial, ovarian, cervical cancer and more

The Healio Editors compiled a list of recent news from the Society of Gynecologic Oncology Annual Meeting held from March 25-28, 2023. Highlights include new data on endometrial cancer drugs; studies on pembrolizumab in endometrial cancer, post-discharge complications after debulking surgery, neoadjuvant olaparib for women with germline-mutant ovarian cancer, and more.

Jill-rollet , Society-of-gynecologic-oncology-annual-meeting , Healio-editors , Gynecologic-oncology-annual-meeting ,

Agenus (AGEN) Q4 2022 Earnings Call Transcript

AGEN earnings call for the period ending December 31, 2022.

Colorado , United-states , American , Mayank-mamtani , Anthony-el-khoueiry , Mike-king , Bree-wilky , Kelly-shi-jefferies , Matt-phipps , Christine-klaskin , Mayank-mamtanib-riley , Emily-bodnar